ESR1 and breast carcinoma: However, due to time and cost constraints in the vast majority of healthcare systems, surrogate molecular classification of breast cancer is still largely based on the immunohistochemical assessment of biomarkers (ER, PR, HER2 and Ki-67) [1,12].